Figure 6
Effects of ERK and AKT inhibitors in primary SCs. Primary SCs were treated with 25 ng/ml of recombinant HGF protein in the presence of 10 μM of U0126 or 10 μM of AKTi. Total RNAs were prepared at 1 hr and subjected to quantitative RT-PCR. Effects on Cell migration and proliferation were measured by Boyden chamber and WST-1 assays, respectively. (A) Effects of U0126 and AKTi on the RNA level of Egr-1, c-Fos, GDNF and Lif. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. HGF only treated group. (B) Effect on SC migration. **p < 0.01, ***p < 0.001, n.s = not significant. (C) Effect on SC proliferation was measured by WST-1 assay. *p < 0.05 vs. control. #p < 0.05 vs. HGF only treated group. (D) Effects of PHA-665752 on gene expression in injured nerve was measured by quantitative RT-PCR. Total RNAs were isolated from sciatic nerve at crush 4 d.p.i, *p < 0.001, **p < 0.01, ***p < 0.001. Values represent the mean ± S.E.M.
